L
LimFlow
Peripheral endovascular technology transforming the treatment of critical limb ischemia
About LimFlow
LimFlow operates in the medical device industry, focusing on providing innovative solutions for patients suffering from Chronic Limb Threatening Ischemia (CLTI). The company’s primary product, the LimFlow Percutaneous Deep Vein Arterialization System, is designed to restore blood flow to the ischemic foot when all other treatment options have been exhausted. This minimally invasive procedure offers new hope to patients who are at risk of amputation due to severe peripheral artery disease (PAD) that has progressed to CLTI.
Read full description
LimFlow serves a niche market of patients with advanced CLTI, who are often left with limited treatment options such as bypass surgery or amputation. By offering a less invasive alternative, LimFlow aims to improve patient outcomes, reduce the need for major surgeries, and enhance the quality of life for these patients.
The company operates on a business-to-business (B2B) model, partnering with hospitals, clinics, and healthcare providers to implement its technology. Revenue is generated through the sale of its medical devices and related services, including training and support for healthcare professionals.
LimFlow's market is primarily in the United States and internationally, where it is conducting clinical trials to validate the efficacy and safety of its system. The company is committed to expanding its reach and making its life-saving technology accessible to more patients globally.
At a glance
- Status
- Acquired
- Founded
- 2016
- Headquarters
- Paris, France
- Employees
- 48
- Open positions
- None listed
- Dealroom signal
- 61.7/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Cardiology and cardiovascular, biotech medtech and e-health, Observatoire Deeptech, Hard Tech, radar de l'innovation, observatoire industrial tech, DT and LS, observatoire healthtech, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning LimFlow.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Nov 2023 | $250M | $250M | Inari Medical | ↗ |
| SERIES AOther financing | Sep 2023 | — | — | M&L Group | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for LimFlow is 3.3K monthly website visits, up 26.9% over the last three months. LimFlow's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
M&L Group
Series B and later5 investors entered at this stage
Bpifrance
Sofinnova Partners- SCSoleus Capital
Longitude Capital- BABalestier
Other known investors1 additional known investor
Inari Medical
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about LimFlow on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See LimFlow’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.